IFNG and Miyoshi myopathy: Tumor biopsies collected before and after treatment were evaluated for the expression of a panel of TAAs known to be highly expressed in >80% of patients with MM and RCC and used to assess the immunological efficacy of the treatment by IFN-γ ELISPOT assay.